Table I.
Aggregated Inclusion Rates for Racial and Ethnic Minorities in NIH-Defined Extramural and Intramural Phase III Trials Reported for FY2018
| Median (Range) | Median (Range) | |
|---|---|---|
| American Indian/Alaska Native | 0.1% (0.0%–0.4%) | 0.2% (0.0%–0.7%) |
| Asiana | 1.0% (0.0%–5.8%) | 1.3% (0.0%–8.0%) |
| Black or African Americanb | 11.9% (4.2%–49.8%) | 8.8% (3.7%–27.8%) |
| Native Hawaiian/Pacific Islander | 0.1% (0.0%–1.1%) | 0.0% (0.0%–1.5%) |
| White | 29.1% (2.4%–57.0%) | 27.1% (5.3%–62.4%) |
| More than One Race | 1.3% (0.1%–9.5%) | 0.9% (0.0%–6.8%) |
| Unknown or Not Reported | 1.6% (0.0%–18.4%) | 1.3% (0.0%–25.8%) |
| Hispanic | 4.2% (0.0%–30.6%) | 4.8% (0.0%–22.4%) |
Fogarty International Center (FIC) reported one phase III clinical trial for FY2018 with a 100% Asian enrollment rate, which is not included in the calculation for the medians and ranges in the table.
National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of General Medical Sciences (NIGMS) reported high enrollment rates for Black/African American (AA) participants, at 49.8% Black/AA female, 22.3% Black/AA male, 0.7% Black/AA unknown; and 37.0% Black/AA female, 27.8% Black/AA male, and 0.0% Black/AA unknown, respectively. Excluding these two agencies, the range for Black/AA enrollment is 4.2%−23.1% for females, 3.7%−20.0% for males, 0.0%−16.8% unknown